NCT04666103 Function Integrity of Neck Anatomy in Thyroid Surgery
| NCT ID | NCT04666103 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wuhan University |
| Condition | Thyroid Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,264 participants |
| Start Date | 2020-12-11 |
| Primary Completion | 2021-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,264 participants in total. It began in 2020-12-11 with a primary completion date of 2021-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recent trends in the management of patients with low-risk papillary thyroid carcinoma who have a nonsuspicious or cytologically benign contralateral nodule call into question the need for routine total thyroidectomy. Although the lobectomy for the unilateral thyroid cancer with contralateral benign nodules is sufficient treatment, some of the patients might suffer from the anxiety of the residual benign thyroid nodule and tend to choose total thyroidectomy, which might be overtreatment. Thermal ablation has been proven to be effective in achieving nodule shrinkage and being also free from major complications. In our institution, intraoperative RFA was a proposed alternative strategy to treat the contralateral benign nodules after the thyroid lobectomy for the malignant lobe, which was found to have a better quality of life on anxiety, physiological health, social family, psychological and sensory mentions with a considerable complication rate.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with unilateral thyroid carcinoma and contralateral benign nodule confirmed by preoperative ultrasound-guided fine-needle aspiration cytology; * Patients with contralateral nodules ≤ 20mm and located in the thyroid gland; * Patients with clinical node-negative cervical compartment at palpation and neck ultrasound. Exclusion Criteria: * Previous history of neck surgery * Previous history of neck radiation therapy
Contact & Investigator
Gaosong Wu, Ph.D.
PRINCIPAL INVESTIGATOR
Department of Breast and Thyroid Surgery, Zhongnan Hospital of Wuhan University
Frequently Asked Questions
Who can join the NCT04666103 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Thyroid Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04666103 currently recruiting?
Yes, NCT04666103 is actively recruiting participants. Contact the research team at Yuanqq11@whu.edu.cn for enrollment information.
Where is the NCT04666103 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT04666103 clinical trial?
NCT04666103 is sponsored by Wuhan University. The principal investigator is Gaosong Wu, Ph.D. at Department of Breast and Thyroid Surgery, Zhongnan Hospital of Wuhan University. The trial plans to enroll 1,264 participants.